References
- Nash DT, Gensini GG, Esente P. Lipid lowering therapy and the progression of coronary artery disease. Circulation 1980: 62(Suppl III): 122
- Wlssler RW, Vesselinovitch D. Borensztajln J, et al. Regression of severe atherosclerosis in cholestyramine-treated rhesus monkeys with or without a low-fat diet. Circulation 1975: 52: 11–6
- Dewar HA. Five-year trial of clofibrate in ischaemic heart disease. Br Heart J 1971 Jan: 33: 145
- Oliver MF. Ischemic heart disease: a secondary prevention trial using clofibrate. Br Med J 1971: 4: 775–84
- Stamler J. The coronary drug trial. JAMA 1975: 231: 360–81
- Moore RB, Buchwald H, Varco RL. The effect of partial ileal bypass on plasma lipoproteins. Circulation 198062(3): 469–76
- Kane JP, Malloy MJ, Tun P. et al. Normalization of low-denslty-lipoprotein levels In heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med 1981: 304(5): 251–8
- Nash DT, Gensinl G. Simon H. et al. The Erysichthon syndrome: progression of coronary atherosclerosis and dietary hyperlipidemia. Circulation 197756(3): 363–5
- Basta LL, Williams C. Kioschos JM, et al. Regression of atherosclerotic stenoslng lesions of the renal arteries and spontaneous cure of systemic hypertension through control of hyperlipidemia. Am J Med 1976: 61(3): 420–3
- Roth D, Kostuk WJ. Noninvasive and invasive demonstration of spontaneous regression of coronary artery disease. Circulation 198062(4): 888–96
- Nash DT. Drug therapy of hyperlipidemia: gemfibrozil and other agents. Medical Times 1982 Apr. 16–24
- Nash DT. Clinical investigation of gemfibrozil: gemfibrozil versus clofibrate. Cardiovas Rev Rep 1982: 3(8): 1207–13